title: Paclitaxel-based combination chemotherapy in advanced non-small cell lung cancer.
abstract: Paclitaxel has proven to be a useful drug for patients with advanced non-small cell lung cancer (NSCLC). Paclitaxel-based combination chemotherapy, particularly with carboplatin, has become a very popular combination in the US. This article will review the conclusions of several studies regarding paclitaxel-based chemotherapy. The data provide evidence that this therapy produces good palliation and prolongation of survival for patients with NSCLC and is superior to older cisplatin-based chemotherapy. These results in patients with advanced disease have important implications for neoadjuvant and/or adjuvant approaches in patients with lower stages of disease, and several studies are ongoing.
authors.affiliation: The Sarah Cannon Cancer Center, 250 25th Av. North, Suite 412, Nashville, TN 37203, USA.
authors.forename: F A
authors.initials: FA
authors.lastname: Greco
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage*
chemical_list: D017239:Paclitaxel